IL6 and VEXAS syndrome: While IL-6 inhibitors and JAK inhibitors appear effective in controlling inflammation, as evidenced by the improvement in symptoms such as skin lesions and edema, as well as laboratory indicators, they seem less effective in addressing the hematological involvement in VEXAS syndrome.